See more : Bossdom Digiinnovation Co., Ltd. (6622.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Alzamend Neuro, Inc. (ALZN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alzamend Neuro, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Life & Banc Split Corp. (LFBCF) Income Statement Analysis – Financial Results
- FLEX LNG Ltd. (0RQ8.L) Income Statement Analysis – Financial Results
- Ramco Industries Limited (RAMCOIND.BO) Income Statement Analysis – Financial Results
- Nu Skin Enterprises, Inc. (NUS) Income Statement Analysis – Financial Results
- RIDE ON EXPRESS HOLDINGS Co., Ltd. (6082.T) Income Statement Analysis – Financial Results
Alzamend Neuro, Inc. (ALZN)
About Alzamend Neuro, Inc.
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 50.74K | 23.07K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -50.74K | -23.07K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 6.46M | 7.45M | 5.20M | 1.31M | 1.07M | 3.70M | 323.40K | 275.05K | 0.00 |
| General & Administrative | 3.24M | 6.68M | 7.12M | 3.64M | 3.35M | 1.31M | 545.12K | 942.51K | 69.46K |
| Selling & Marketing | 247.33K | 742.60K | 17.65K | 0.00 | 0.00 | 0.00 | 29.91K | 330.84K | 0.00 |
| SG&A | 3.48M | 7.42M | 7.12M | 3.64M | 3.35M | 1.31M | 575.03K | 1.27M | 69.46K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.94M | 14.87M | 12.32M | 4.95M | 4.42M | 5.01M | 898.43K | 1.55M | 69.46K |
| Cost & Expenses | 9.94M | 14.87M | 12.32M | 4.95M | 4.42M | 5.01M | 898.43K | 1.55M | 69.46K |
| Interest Income | 0.00 | 7.70 | 46.52 | 1.71K | 13.93K | 146.39K | 33.23K | 21.50K | 0.00 |
| Interest Expense | 10.10K | 7.70K | 46.52K | 158.80K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 50.74K | 23.07K | 3.55K | 4.95M | 4.42M | 5.01M | 898.43K | 1.55M | 69.46K |
| EBITDA | -9.89M | -14.85M | -12.32M | 0.00 | 0.00 | 0.00 | 7.34K | -21.50K | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.94M | -14.87M | -12.32M | -4.95M | -4.42M | -5.01M | -898.43K | -1.55M | -69.46K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -10.10K | -7.70K | -42.52K | -94.68K | 13.93K | 146.39K | -33.23K | -21.50K | 0.00 |
| Income Before Tax | -9.95M | -14.88M | -12.36M | -5.05M | -4.41M | -4.86M | -931.66K | -1.57M | -69.46K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -144.83K | 42.52K | 157.10K | -13.93K | -146.39K | -898.43K | -21.50K | 0.00 |
| Net Income | -9.95M | -14.88M | -12.40M | -5.20M | -4.40M | -4.86M | -931.66K | -1.57M | -69.46K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -14.72 | -22.89 | -20.92 | -10.75 | -9.26 | -12.40 | -1.64 | -8.18 | -0.42 |
| EPS Diluted | -14.70 | -22.89 | -20.88 | -10.74 | -9.25 | -12.40 | -1.64 | -8.18 | -0.42 |
| Weighted Avg Shares Out | 676.00K | 650.00K | 593.00K | 484.00K | 475.00K | 392.00K | 568.70K | 192.00K | 165.00K |
| Weighted Avg Shares Out (Dil) | 676.57K | 650.13K | 593.97K | 484.33K | 475.02K | 392.29K | 568.70K | 192.01K | 165.30K |
Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s
TAMPA, Fla.--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that it has received confirmation that topline data for its Phase...
Are These Penny Stocks on Your Watchlist This Week?
Check these penny stocks out for your watchlist this week The post Are These Penny Stocks on Your Watchlist This Week? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Best Biotech Penny Stocks to Buy in November? 3 to Watch Now
Which biotech penny stocks are you watching this month? The post Best Biotech Penny Stocks to Buy in November?
ALZN Stock: Why Is Little-Known Alzamend Neuro Gaining Today?
Today, investors in preclinical biotech company Alzamend Neuro and ALZN stock are seeing impressive gains of more than 25% currently. The post ALZN Stock: Why Is Little-Known Alzamend Neuro Gaining Today?
ALZN Stock Price: Why It Substantially Increased Today
The stock price of Alzamend Neuro Inc (NASDAQ: ALZN) increased by 35.09% today. This is why it happened.
See Why Alzamend Neuro Stock Is Rallying On Thursday
Alzamend Neuro Inc (NASDAQ: ALZN) has received a written response to its meeting request regarding the FDA's Type B Pre‑Investigational New Drug (Pre-IND) application. Today's response provides a path for its planned clinical development of AL002, the Company says.
ALZN Stock: The Alzheimer's Clinical Trial News That Has Alzamend Neuro Soaring Today
Alzamend Neuro (ALZN) stock is on the move Thursday after getting an update from the U.S. Food and Drug Administration (FDA). The post ALZN Stock: The Alzheimer's Clinical Trial News That Has Alzamend Neuro Soaring Today appeared first on InvestorPlace.
Why Alzamend Neuro Shares Are Surging Higher Today
Alzamend Neuro Inc (NASDAQ: ALZN) is surging higher Thursday after the company announced it received a written response to its meeting request relating to its Type B Pre‑IND application from the FDA providing a path for Alzamend's planned clinical development of...
Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients’ Immunological System to Combat Alzheimer’s Disease
TAMPA, Fla.--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that it has received a written response to its meeting request...
Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s Disease
TAMPA, Fla.--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that the first group of healthy participants have been dosed in...
Source: https://incomestatements.info
Category: Stock Reports